ATE138578T1 - Behandlung von insulinresistentem diabetes - Google Patents

Behandlung von insulinresistentem diabetes

Info

Publication number: ATE138578T1
Authority: AT; Austria
Prior art keywords: treatment; resistant diabetes; insulin resistant; insulin; diabetes
Prior art date: 1989-09-08

Application number

AT90913512T

Other languages

English (en)

Inventor

Angus Carstairs Glasg Maccuish

Original Assignee

Fujisawa Pharmaceutical Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-09-08

Filing date

1990-09-10

Publication date

1996-06-15

1990-09-10 Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co

1996-06-15 Application granted granted Critical

1996-06-15 Publication of ATE138578T1 publication Critical patent/ATE138578T1/de

Links

206010022491 Insulin resistant diabetes Diseases 0.000 title abstract 2
201000005948 Donohue syndrome Diseases 0.000 abstract 2
108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 2
102000013275 Somatomedins Human genes 0.000 abstract 2
206010053547 Congenital generalised lipodystrophy Diseases 0.000 abstract 1
201000006705 Congenital generalized lipodystrophy Diseases 0.000 abstract 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
208000035369 Leprechaunism Diseases 0.000 abstract 1
206010024604 Lipoatrophy Diseases 0.000 abstract 1
201000011032 Werner Syndrome Diseases 0.000 abstract 1
239000008103 glucose Substances 0.000 abstract 1
208000022215 lipoatrophic diabetes Diseases 0.000 abstract 1
201000009099 lipoatrophic diabetes mellitus Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Diabetes (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Endocrinology (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT90913512T 1989-09-08 1990-09-10 Behandlung von insulinresistentem diabetes ATE138578T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB898920381A GB8920381D0 (en)	1989-09-08	1989-09-08	Treatment of insulin-resistant diabetes

Publications (1)

Publication Number	Publication Date
ATE138578T1 true ATE138578T1 (de)	1996-06-15

Family

ID=10662782

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT90913512T ATE138578T1 (de)	1989-09-08	1990-09-10	Behandlung von insulinresistentem diabetes

Country Status (11)

Country	Link
US (1)	US5674845A (de)
EP (1)	EP0490955B1 (de)
JP (1)	JP2513360B2 (de)
AT (1)	ATE138578T1 (de)
AU (1)	AU642665B2 (de)
CA (1)	CA2066227A1 (de)
DE (1)	DE69027217T2 (de)
DK (1)	DK0490955T3 (de)
ES (1)	ES2087162T3 (de)
GB (1)	GB8920381D0 (de)
WO (1)	WO1991003253A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5681814A (en) *	1990-06-07	1997-10-28	Genentech, Inc.	Formulated IGF-I Composition
SE9201573D0 (sv) *	1992-05-19	1992-05-19	Kabi Pharmacia Ab	Use of igf-1
AU670951B2 (en) *	1992-06-08	1996-08-08	Chiron Corporation	Use of growth factor IGF-I and/or IGF-II
WO1994016722A1 (en) *	1993-01-25	1994-08-04	The Beth Israel Hospital Association	Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties
SE9402370D0 (sv)	1994-07-04	1994-07-04	Pharmacia Ab	Use of IGF-I
US5565428A (en) *	1995-05-22	1996-10-15	Genentech, Inc.	Method of administration of IGF-I
US5741776A (en) *	1995-05-22	1998-04-21	Genentech, Inc.	Method of administration of IGF-I
US5783556A (en) *	1996-08-13	1998-07-21	Genentech, Inc.	Formulated insulin-containing composition
CA2276149A1 (en) *	1996-12-24	1998-07-02	Fred I. Chasalow	Methods for treating insulin resistance and identifying patients at risk for the disease
US6121416A (en)	1997-04-04	2000-09-19	Genentech, Inc.	Insulin-like growth factor agonist molecules
US6420518B1 (en)	1997-04-04	2002-07-16	Genetech, Inc.	Insulin-like growth factor agonist molecules
US6627746B1 (en)	1998-04-17	2003-09-30	Exelixis, Inc.	Nucleic acids and proteins of C. elegans insulin-like genes and uses thereof
MXPA01000032A (es) *	1998-07-08	2002-10-17	Kirin Amgen Inc	Preparacion que contiene farmaco de alto peso molecular en forma de polvo para administracion mucosal.
JP3141107B2 (ja) *	1998-11-16	2001-03-05	工業技術院長	ヒト由来ブラディオン蛋白質、それをコードするｄｎａ及びそれらの使用
US6902898B2 (en) *	1998-11-16	2005-06-07	National Institute Of Advanced Industrial Science And Technology	Human derived bradeion proteins, DNA coding for the proteins, and uses thereof
DE60016560T2 (de)	1999-01-06	2005-12-15	Genentech, Inc., South San Francisco	Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i)
DK1165119T3 (da)	1999-04-08	2003-12-15	Genentech Inc	Sammensætning baseret på modsat ladede polypeptider
US6040292A (en) *	1999-06-04	2000-03-21	Celtrix Pharmaceuticals, Inc.	Methods for treating diabetes
DE60133271T2 (de)	2000-05-16	2009-04-23	Genentech, Inc., South San Francisco	Behandlung von knorpelerkrankungen
EP1772464B1 (de)	2001-02-09	2009-08-12	Genentech, Inc.	Verfahren zur Identifizierung von indirekten IGF-1-Agonisten
WO2002072780A2 (en)	2001-03-14	2002-09-19	Genentech, Inc.	Igf antagonist peptides
US20040138116A1 (en) *	2002-08-30	2004-07-15	Vincent Geenen	Tolerogenic approach for type 1 diabetes
EP3609522A4 (de) *	2017-04-10	2021-05-05	Yoram Palti	Verfahren und verbindungen zur behandlung von diabetes
WO2022079612A1 (en) *	2020-10-13	2022-04-21	Betavive Ltd.	Method and compounds for treating diabetes and associated metabolic diseases
US12447198B2 (en)	2021-10-12	2025-10-21	Betavive Ltd.	Peptides and fragments for treating diabetes and associated metabolic diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU624596B2 (en) *	1987-12-16	1992-06-18	Genesis Systems Corporation	Method and system for detection and treatment of premenstrual syndrome
US4988675A (en) *	1988-02-05	1991-01-29	Ciba-Geigy Corporation	Method for preventing secondary effects
GB8819826D0 (en) *	1988-08-20	1988-09-21	Kabivitrum Ab	Glycosylated igf-1

1989
- 1989-09-08 GB GB898920381A patent/GB8920381D0/en active Pending
1990
- 1990-09-10 EP EP90913512A patent/EP0490955B1/de not_active Expired - Lifetime
- 1990-09-10 DE DE69027217T patent/DE69027217T2/de not_active Expired - Lifetime
- 1990-09-10 DK DK90913512.1T patent/DK0490955T3/da active
- 1990-09-10 AT AT90913512T patent/ATE138578T1/de not_active IP Right Cessation
- 1990-09-10 AU AU63580/90A patent/AU642665B2/en not_active Ceased
- 1990-09-10 ES ES90913512T patent/ES2087162T3/es not_active Expired - Lifetime
- 1990-09-10 CA CA002066227A patent/CA2066227A1/en not_active Abandoned
- 1990-09-10 JP JP2512643A patent/JP2513360B2/ja not_active Expired - Lifetime
- 1990-09-10 WO PCT/GB1990/001399 patent/WO1991003253A1/en not_active Ceased
1995
- 1995-03-27 US US08/412,222 patent/US5674845A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2066227A1 (en)	1991-03-09
DE69027217T2 (de)	1996-10-02
AU6358090A (en)	1991-04-08
JPH05504547A (ja)	1993-07-15
WO1991003253A1 (en)	1991-03-21
EP0490955B1 (de)	1996-05-29
DE69027217D1 (de)	1996-07-04
US5674845A (en)	1997-10-07
GB8920381D0 (en)	1989-10-25
AU642665B2 (en)	1993-10-28
EP0490955A1 (de)	1992-06-24
ES2087162T3 (es)	1996-07-16
JP2513360B2 (ja)	1996-07-03
DK0490955T3 (da)	1996-06-24

Legal Events

Date	Code	Title	Description
2010-12-15	EELA	Cancelled due to lapse of time

Publication	Publication Date	Title
DE69027217D1 (de)	1996-07-04	Behandlung von insulinresistentem diabetes
MY101026A (en)	1991-06-29	An improved method for administering insulin.
SE8703625D0 (sv)	1987-09-18	New medical use
ATE50493T1 (de)	1990-03-15	Ibuprofen enthaltendes arzneimittel.
RU97104029A (ru)	1999-04-20	Лечение сахарного диабета типа ii агонистами амилина
CA2196999A1 (en)	1996-12-19	Treatment of type ii diabetes mellitus with amylin agonists
SE9201573D0 (sv)	1992-05-19	Use of igf-1
ATE109979T1 (de)	1994-09-15	Verwendung von guanidinderivaten zur herstellung eines arzneimittels mit npy-antagonistischer wirkung.
IE873245L (en)	1988-06-17	Administering a deoxythymidine
DE3770830D1 (de)	1991-07-25	Zubereitung von pregnanolol in einer stabilen oel-in-wasser-emulsion.
BG60324B2 (en)	1994-07-25	New somatotropines
DE3781488D1 (de)	1992-10-08	Pharmazeutische zusammensetzung, enthaltend 2',3'-dideoxycytidin-2'-en(2',3'-dideoxy-2',3'-didehydrocytidin) zur behandlung von mit retrovirus infizierten patienten.
IE822064L (en)	1983-02-27	Composition containing human insulin and c-peptide
KR890004690A (ko)	1989-05-09	당뇨병의 치료를 위한 베자피브레이드의 용도
DE69600367D1 (de)	1998-07-23	Verwendung von Sulfasalazin und/oder dessen aktiven Metaboliten zur Herstellung eines Arzneimittels zur Behandlung von venöser Insuffizienz und venösen Ulcera
KR910002456A (ko)	1991-02-25	당뇨병 치료용 제약 조성물
HUT45250A (en)	1988-06-28	Process for producing 5-substituted octahydro-indolysin derivatives and pharmaceutical compositions containing them as active components
KR910002450A (ko)	1991-02-25	당뇨병 치료용 제약 조성물
KR880000094A (ko)	1988-03-23	위염치료제
JPS6463342A (en)	1989-03-09	Stabilization of glutathione-containing composition
KR880001630A (ko)	1988-04-25	5-플루오로우라실 유도체 및 그의 용도
KR880013936A (ko)	1988-12-22	강심성 트리사이클릭 이미다졸론
KR840004431A (ko)	1984-10-15	히단토인 치료제
SE7706192L (sv)	1977-11-29	Antimikrobielle paste
KR880009017A (ko)	1988-09-13	항바이러스 활성을 갖는 이속사졸 유도체 및 이를 함유하는 약제